865663-98-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 2-fluoro-5-(methylsulfonyl)-, methyl ester is used as an intermediate in the synthesis of various pharmaceutical products. Its unique structure and functional groups make it a valuable component in the development of new drugs and therapeutic agents.
Used in Chemical Research and Development:
Benzoic acid, 2-fluoro-5-(Methylsulfonyl)-, Methyl ester also serves as a building block in the synthesis of various organic compounds. Researchers and chemists use it to create new molecules with potential applications in different fields, such as materials science, agrochemicals, and specialty chemicals.
Used in Antitumor and Anticancer Applications:
Benzoic acid, 2-fluoro-5-(methylsulfonyl)-, methyl ester has been studied for its potential therapeutic applications, including its antitumor and anticancer properties. Its unique structure may contribute to its ability to target and inhibit the growth of cancer cells, making it a promising candidate for further research and development in oncology.
As with any chemical compound, it is essential to take proper precautions when handling and using Benzoic acid, 2-fluoro-5-(methylsulfonyl)-, methyl ester to ensure safety and minimize potential risks.

Upstream product

• 37098-75-2 2-fluoro-5-chlorosulfonylbenzoic acid 
• 74-88-4 methyl iodide 
• 1229627-84-2 2-fluoro-5-sulfinobenzoic acid 

Downstream Products

• 247569-56-8 2-fluoro-5-(methylsulfonyl)benzoic acid 
• 909799-55-9 methyl 5-(methylsulfonyl)-2-(1-piperidinyl)benzoate 
• 845616-82-2 5-methane-sulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzoic acid 
• 845614-11-1 Bitopertin 

Relevant academic research and scientific papers

Bitopertin synthetic method and intermediate

The present invention discloses a new synthesis method and intermediates of Bitopertin. According to the Bitopertin synthesis method, 5-methylsulfonyl-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzoic acid is adopted as a raw material, and continuous multi-step operations such as chlorination, acylation, deprotection, condensation and re-crystallization are subjected to performed to obtain the Bitopertin, wherein the intermediates in each step do not require further purification, and the total yield can achieve more than or equal to 80%.

2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue with a formula (I) compound and a preparation method and application thereof, wherein substitutions in the formula (I) compound are defined as in the description. This serial compound can inhibit the activity of glycine transport protein-1 (GlyT1), is useful in treating related diseases in central nerve and psychological fields, for example, schizophrenia (including positive symptoms, negative symptoms and cognitive symptoms), senile dementia, Parkinson's disease and other related psychological diseases, is widely applicable to the drugs for preventing and treating central nerve and psychological diseases, and is expected to be developed into new-generation GlyT1 inhibitors.

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.